BioSpace News Archive

Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced its financial results for the fourth quarter of 2020, and provided an overview of recent business highlights

Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2020.

Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, will report fourth quarter and full year 2020 financial results after market close on Thursday, February 25, 2021

OPKO Health, Inc. reports business highlights and financial results for the three months ended December 31, 2020.

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will participate in a virtual fireside chat, as well as host virtual investor meetings, at the 10 th Annual SVB Leerink Global Healthcare Conference on February 25, 2021.

SQI Diagnostics Inc., a precision medicine company that discovers, develops, and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, is proud to announce the launch of its newly redesigned website at https://www.sqidiagnostics.com.

DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it plans to release its fourth quarter 2020 financial results after the market closes on Thursday, March 4, 2021. In conjunction with such release, DermTech plans to host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

Alnylam to Webcast Presentation at 10 th Annual SVB Leerink Global Healthcare Conference

Arena Pharmaceuticals, Inc. announced that on February 15, 2021, the Compensation Committee of its Board of Directors granted to eleven new employees inducement stock options to purchase an aggregate of 33,885 shares of its common stock and 8,475 inducement restricted stock units.

Lyndra Therapeutics , a clinical-stage biotechnology company working to make daily pills a thing of the past with the first-ever ultra-long-acting, sustained release oral therapies, today announced that members of its management team will participate in the SVB Leerink 10th Annual Global Healthcare Conference being held virtually February 22-26, 2021.